Jafral

What Jafral does

JAFRAL, Biotechnological Research and Development, d.o.o. (branded Jafral) is a Slovenia-based contract development and manufacturing organization (CDMO) founded in 2011 and headquartered in Ljubljana, where it operates a GMP-certified facility at Stegne 13A. The company is privately held, employs 11-50 people, and serves pharmaceutical, biotechnology, cosmetics, animal health, food/nutrition, and agriculture clients across more than 50 countries.

Its technology platform centers on microbial fermentation-based biomanufacturing, covering bacteriophages (the company's flagship modality, in which it claims to be one of the world's largest manufacturers), plasmid DNA, messenger RNA, recombinant proteins (including cell-free synthetic systems), Outer Membrane Vesicles, and Live Biotherapeutic Products. The integrated service stack spans upstream processing, downstream purification, GMP-compliant clinical and commercial production, and Fill & Finish capabilities including sterile liquid filling, lyophilization, encapsulation, and spray-drying. Reported technical benchmarks include batch sizes up to 200 L, weekly capacity of 600 L, and upstream/downstream optimization yielding up to 10-fold improvements in average yield, supported by more than 150 cell/viral banks produced, 120+ drug substances/APIs, 14+ clinical drug products, and 200+ specific analytical methods developed.

Commercially, JAFRAL operates a fee-for-service B2B model with project-based quotes scoped to batch size, regulatory grade (research, preclinical, or GMP), and service mix. Go-to-market is executed through direct enterprise field sales, an owned annual Phage Summit, and active participation in industry events (ASM Microbe, ESCMID, BIO-Europe, Phage Futures, VoM, Advanced Therapies Europe). Pricing is not publicly disclosed, revenue is not reported, and no institutional funding rounds are documented in the data; growth has been organically funded and externally validated by the 2025 GAZELA Silver National and Central Slovenia awards for fast-growing companies.

Name

Jafral

Legal name

JAFRAL, Biotechnological Research and Development, d.o.o.

Website

https://jafral.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

JAFRAL is a Slovenia-based, GMP-certified CDMO specializing in microbial fermentation manufacturing of bacteriophages and biologicals (pDNA, mRNA, recombinant proteins, OMVs, LBPs) for pharmaceutical, animal health, food, agriculture, and cosmetics clients across 50+ countries.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing (CDMO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Contract manufacturing services
• Bacteriophage production
• Biological CDMO services
• GMP-compliant manufacturing
• Sterile fill and finish

Headquarters

HQ city

Ljubljana

HQ country

Slovenia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Contract development and manufacturing services: JAFRAL generates revenue as a CDMO by providing fee-for-service contract development and manufacturing of bacteriophages and biologicals (pDNA, mRNA, recombinant proteins, OMVs, LBPs) for pharmaceutical, biotechnology, cosmetics, veterinary, and food industry clients. Services span from R&D and preclinical through GMP clinical trial material to commercial production, with pricing based on project scope, batch size, and regulatory requirements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Jafral is a contract development and manufacturing organization (CDMO) providing end-to-end GMP-compliant production services for bacteriophages and biologicals including plasmid DNA (pDNA), messenger RNA (mRNA), recombinant proteins, Outer Membrane Vesicles (OMVs), and Live Biotherapeutic Products (LBPs). Services span from R&D and preclinical development through GMP clinical trial material to commercial production, and include integrated Fill & Finish capabilities (liquid filling, lyophilization, encapsulation, spray-drying) with batch sizes up to 200 L. The company serves pharmaceutical, biotechnology, cosmetics, animal healthcare, agriculture, and food industry clients across 50+ countries.

Product overview

Jafral is a contract research and manufacturing organization (CRO/CDMO) specializing in the production of biologicals, offering a portfolio of distinct products and services built around two core technology pillars: Bacteriophages and Biologicals (Plasmid DNA, mRNA, Recombinant Proteins, OMVs, LBPs). The Bacteriophages line covers the full lifecycle from discovery through GMP clinical trial material, with five therapeutic-area sub-products (human therapeutics, veterinary, food supplements, agriculture, dermatology). The Biologicals line includes five molecular platform products (pDNA, mRNA, Recombinant Proteins, OMVs, LBPs), each available from R&D through GMP scale. A dedicated Fill & Finish service provides GMP-certified sterile formulation and packaging across liquid, lyophilized, encapsulated, and spray-dried formats. The portfolio is unified by shared capabilities in cell banking, process development, analytical testing, and regulatory support, serving pharmaceutical, cosmetics, animal healthcare, and food industries.

Differentiator

Problem solved

Functional benefit

Products and services

• Bacteriophage Manufacturing Services

Quantifiable outcome

• Up to 10-fold yield improvements through optimized upstream and downstream techniques
• +4 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• PhageEU CoalitioncoreStrategic or Co-development PartnerJAFRAL is a founding member of the PhageEU Coalition, a European coalition focused on advancing phage therapy and promoting sustainable phage therapy frameworks within the EU. This strategic membership positions JAFRAL at the center of EU policy and regulatory discussions on bacteriophage therapy.
• NexaBiomecoreStrategic or Co-development PartnerJAFRAL Biosolutions partnered with NexaBiome for industrial-scale phage production, combining JAFRAL's GMP manufacturing capabilities with NexaBiome's phage technology and applications expertise.
• SCTbio and Oslo University HospitalcoreStrategic or Co-development PartnerJAFRAL partnered with SCTbio and Oslo University Hospital on next-generation CAR-T therapy development, contributing manufacturing expertise for cell and gene therapy applications.
• IMMOONITY Project consortiumminorStrategic or Co-development PartnerJAFRAL joined the IMMOOONITY project consortium to advance sustainable bovine immunotherapy, contributing phage-based manufacturing capabilities to the project.
• SmartGene.SiminorStrategic or Co-development PartnerJAFRAL is a partner in the SmartGene.Si project focused on innovative approaches to gene therapy, contributing to Slovenia's first cancer gene therapy trial.
• International Society for Viruses of Microorganisms (ISVM)minorGTM or Marketing PartnerJAFRAL became an official sponsor of ISVM, supporting the international scientific community focused on viruses of microorganisms and increasing brand visibility among key researchers and scientists.
• PhageDirectoryminorGTM or Marketing PartnerJAFRAL sponsors the PhageDirectory team, a phage-related directory and resource platform, supporting the phage research community and building brand awareness.
• INCATE (Incubator for Antibacterial Therapies)minorStrategic or Co-development PartnerJAFRAL participated in an INCATE workshop at the 8th AMR Conference in Basel, engaging with the antibiotic resistance incubator network focused on phage therapy development.
• EU-JAMRAI 2minorStrategic or Co-development PartnerJAFRAL was invited to EU-JAMRAI 2 discussions on sustainable phage therapy, contributing to EU-level antimicrobial resistance policy discussions.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/jafral1
• LinkedInlinkedin.com/company/jafral-biosolutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jafral